ReviewFrontiers in immunology2020
COVID-19: Coronavirus Vaccine Development Updates.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety of COVID-19 vaccination in women undergoing IVF/ICSI treatment - Clinical study and systematic review.Frontiers in immunology · 2022Pooled it
- Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial.Infectious diseases of poverty · 2021Trial
- Synthesis and Assembly of a New-generation Bifunctional Lipid Nanoparticle for Selective Delivery of mRNA to Antigen Presenting Cells.bioRxiv : the preprint server for biology · 2026Article
- Synergistic Effect of Guanidinium and Tertiary Amine Groups on Boosting Gene Delivery.JACS Au · 2025Article
- Rural-Urban Disparities in COVID-19 Vaccine Uptake and Associated Mortality and Cardiovascular Disease Outcomes in the United States.Vaccines · 2025Review
- Virus and cell specific HMGB1 secretion and subepithelial infiltrate formation in adenovirus keratitis.PLoS pathogens · 2025Article
- Antibody-dependent enhancement of coronaviruses.International journal of biological sciences · 2025Review
- The acceptance of COVID-19 vaccines in Rwanda: a cross-sectional study.BMC public health · 2024Article
- From ancient remedies to modern miracles: tracing the evolution of vaccines and their impact on public health.3 Biotech · 2024Review
- Surveillance Metrics and History of the COVID-19 Pandemic in Central Asia: Updated Epidemiological Assessment.JMIR public health and surveillance · 2024Article
- Synthesis of a dendritic cell-targeted self-assembled polymeric nanoparticle for selective delivery of mRNA vaccines to elicit enhanced immune responses.Chemical science · 2024Article
- MultiTEP-Based Vaccines Targeting SARS-CoV-2 Spike Protein IgG Epitopes Elicit Robust Binding Antibody Titers with Limited Virus-Neutralizing Activity.Pathogens (Basel, Switzerland) · 2024Article
- Have Previous COVID-19 Vaccinations Shaped the Potential Enhancing Infection of Variant Strains?Vaccines · 2024Article
- Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.Nature communications · 2024Article
- Causality between COVID-19 and multiple myeloma: a two-sample Mendelian randomization study and Bayesian co-localization.Clinical and experimental medicine · 2024Article
- Article
- Development of a quantum dot-based lateral flow immunoassay strip for rapid and sensitive detection of SARS-CoV-2 neutralizing antibodies.Scientific reports · 2023Article
- Transmembrane serine protease 2, a SARS-CoV-2 internalization protease, correlates with clinical outcome, molecular features, and immunotherapy response in colorectal cancer.Journal of gastrointestinal oncology · 2023Article
- Analysis of ethical considerations of COVID‑19 vaccination: lessons for future.BMC medical ethics · 2023Article
- Review
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since March 2020 and led to many fatalities. Vaccines represent the most efficient means to control and stop the pandemic of COVID-19. However, currently there is no effective COVID-19 vaccine approved to use worldwide except for two human adenovirus vector vaccines, three inactivated vaccines, and one peptide vaccine for early or limited use in China and Russia. Safe and effective vaccines against COVID-19 are in urgent need. Researchers around the world are developing 213 COVID-19 candidate vaccines, among which 44 are in human trials. In this review, we summarize and analyze vaccine progress against SARS-CoV, Middle-East respiratory syndrome Coronavirus (MERS-CoV), and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus like particles, nucleic acid vaccines, and viral vector vaccines. As SARS-CoV-2, SARS-CoV, and MERS-CoV share the common genus,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.